The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments
Increasing syphilis cases, stronger STI surveillance initiatives, and growing emphasis on early diagnosis are expected to support sustained demand
The approval marks a major milestone in the global fight against antimicrobial resistance
The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival
The company plans to establish similar healthcare centres across universities, schools, and corporate campuses nationwide
Selected ventures to receive grants and structured intellectual property support to strengthen protection and management of healthcare innovations
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
Subscribe To Our Newsletter & Stay Updated
